
Iovance Biotherapeutics Inc IOVA.O:
IOVANCE ANNOUNCES FIVE-YEAR RESULTS OF AMTAGVI® (LIFILEUCEL) IN PATIENTS WITH ADVANCED MELANOMA AT ASCO ANNUAL MEETING
IOVANCE BIOTHERAPEUTICS INC: ONE-TIME AMTAGVI TREATMENT DEMONSTRATED DURABLE RESPONSES AND A FIVE-YEAR OVERALL SURVIVAL RATE OF 20%